Results 41 to 50 of about 4,805 (202)

A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. [PDF]

, 2022
PURPOSE: Selinexor is the first selective inhibitor of nuclear export to be approved for the treatment of relapsed or refractory multiple myeloma (MM).
Agte, Sarita, Aleman, Adolfo, Bhalla, Sherry, Chari, Ajai, Cho, Hearn, Ghodke-Puranik, Yogita, Jagannath, Sundar, Jiang, Joy, Laganà, Alessandro, Landesman, Yosef, Leshchenko, Violetta, Madduri, Deepu, Melnekoff, David, Parekh, Samir, Restrepo, Paula, Richard, Shambavi, Richter, Joshua, Walker, Christopher   +17 more
core   +1 more source

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts

Translational Oncology, 2021
Gain-of-function Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations occur in 25% of lung adenocarcinomas, and these tumors are challenging to treat.
Joshua C. Rosen, Jessica Weiss, Nhu-An Pham, Quan Li, Sebastiao N. Martins-Filho, Yuhui Wang, Ming-Sound Tsao, Nadeem Moghal   +7 more
doaj   +1 more source

New agents in the Treatment of Myeloma Bone Disease [PDF]

, 2017
Patients with multiple myeloma develop a devastating bone disease driven by the uncoupling of bone remodelling, excess osteoclastic bone resorption and diminished osteoblastic bone formation.
Chantry, A.D., Jolley, I., Lawson, M.A., Ring, E.S., Snowden, J.A.   +4 more
core   +2 more sources

Selinexor and COVID-19: The Neglected Warden

Frontiers in Pharmacology, 2022
A novel severe acute respiratory distress syndrome coronavirus type 2 (SARS-CoV-2) has been confirmed as the cause of the global pandemic coronavirus disease 2019 (COVID-19). Different repurposed drugs have been trialed and used in the management of COVID-19. One of these agents was the anti-cancer Selinexor (SXR).
Gomaa Mostafa-Hedeab, Gomaa Mostafa-Hedeab, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Nermeen N. Welson, Gaber El-Saber Batiha, Carlos Adam Conte-Junior   +6 more
openaire   +3 more sources

Diagnostic accuracy of depression questionnaires in adult patients with diabetes: a systematic review and meta-analysis [PDF]

, 2019
Importance Comorbid depression is common among patients with diabetes and has severe health consequences, but often remains unrecognized. Several questionnaires are used to screen for depression.
Adriaanse, Marcel C, Bosmans, Judith E, de Boer, Michiel R, de Joode, Johanna W, van Dijk, Susan E M, van Marwijk, Harm W J, van Tulder, Maurits W, Walburg, Florine S   +7 more
core   +3 more sources

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma

Journal of Translational Medicine, 2023
Background Extramedullary disease usually implies a dismal outcome in relapsed/refractory multiple myeloma patients, and requires novel treatment approaches.
Di Wang, Haiying Fu, Yimei Que, Haitao Ruan, Menglei Xu, Xiaolu Long, Qiuxia Yu, Chunhui Li, Zhe Li, Songbai Cai, Wei Chen, Cong Sun, Guang Hu, Shuai Wang, Donggou He, Jianming Mei, Wen Wang, Chunrui Li   +17 more
doaj   +1 more source

Designing a broad-spectrum integrative approach for cancer prevention and treatment [PDF]

, 2015
Targeted therapies and the consequent adoption of "personalized" oncology have achieved notablesuccesses in some cancers; however, significant problems remain with this approach. Many targetedtherapies are highly toxic, costs are extremely high, and most
Amedei, A., Amin, A., Amin, A.R.M.R., Aquilano, K., Arbiser, J., Arreola, A., Arzumanyan, A., Ashraf, S.S., Azmi, A.S., Benencia, F., Bhakta, D., Bilsland, A., Bishayeen, A., Blain, S.W., Block, K.I., Block, P.B., Boosani, C.S., Carey, T.E., Carnero, A., Carotenuto, M., Casey, S.C., Chakrabarti, M., Chaturvedi, R., Chen, G.Z., Chen, S., Chen, Y.C., Chenx, H., Choi, B.K., Ciriolo, M.R., Coley, H.M., Collins, A.R., Connell, M., Crawford, S., Curran, C.S., Dabrosin, C., Damia, G., Dasgupta, S., DeBerardinis, R.J., Decker, W.K., Dhawan, P., Diehl, A.M.E., Dong, J-T., Dou, Q.P., Drew, J.E., El-Rayes, B., Elkord, E., Feitelson, M.A., Felsher, D.W., Ferguson, L.R., Fimognari, C., Firestone, G.L., Frezza, C., Fujii, H., Fuster, M.M., Generali, D., Georgakilas, A.G., Gieseler, F., Gilbertson, M., Green, M.F., Grue, B., Guha, G., Gyllenhaal, C., Halicka, D., Helferich, W.G., Heneberg, P., Hentosh, P., Hirschey, M.D., Hofseth, L.J., Holcombe, R.F., Honoki, K., Hsu, H-Y., Huang, G.S., Jensen, L.D., Jiang, W.G., Jones, L.W., Karpowicz, P.A., Keith, W.N., Kerkar, S.P., Khan, G.N., Khatami, M., Ko, Y.H., Kucuk, O., Kulathinal, R.J., Kumar, N.B., Kumara, H.M.C.S., Kwon, B.S., Le, A., Lea, M.A., Lee, H-Y., Lichtor, T., Lin, L-T., Locasale, J.W., Lokeshwar, B.L., Longo, V.D., Lowe, L., Lyssiotis, C.A., MacKenzie, K.L., Malhotra, M., Marino, M., Martinez-Chantar, M.L., Matheu, A., Maxwell, C., McDonnell, E., Meeker, A.K., Mehrmohamadi, M., Mehta, K., Michelotti, G.A., Mohammad, R.M., Mohammed, S.I., Morre, D.J., Muqbil, I., Muralidhar, V., Murphy, M.P., Nagaraju, G.P., Nahta, R., Niccolai, E., Nowsheen, S., Panis, C., Pantano, F., Parslow, V.R., Pawelec, G., Pedersen, P.L., Poore, B., Poudyal, D., Prakash, S., Prince, M., Raffaghello, L., Rathmell, J.C., Rathmell, W.K., Ray, S.K., Reichrath, J., Rezazadeh, S., Ribatti, D., Ricciardiello, L., Robey, R.B., Rodier, F., Rupasinghe, H.P.V., Russo, G.L., Ryan, E.P., Samadi, A.K., Sanchez-Garcia, I., Sanders, A.J., Santini, D., Sarkar, M., Sasada, T., Saxena, N.K., Shackelford, R.E., Sharma, D., Shin, D.M., Sidransky, D., Siegelin, M.D., Signori, E., Singh, N., Sivanand, S., Sliva, D., Smythe, C., Spagnuolo, C., Stafforini, D.M., Stagg, J., Subbarayan, P.R., Sundin, T., Talib, W.H., Thompson, S.K., Tran, P.T., Ungefroren, H., Vander Heiden, M.G., Venkateswaran, V., Vinay, D.S., Vlachostergios, P.J., Wang, Z., Wellendx, K.E., Whelan, R.L., Yang, E.S., Yang, H., Yang, X., Yaswen, P., Yedjou, C., Yin, X., Zhu, J., Zollo, M.   +179 more
core   +1 more source

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma

Experimental Hematology & Oncology, 2023
Leiomyosarcoma (LMS) is a rare soft tissue sarcoma (STS) that begins in smooth muscle tissue and most often initiates in the abdomen or uterus. Compared with other uterine cancers, uterine LMS (ULMS) is an aggressive tumor with poor prognosis and a high ...
Sonam Mittal, Ishaque Pulikkal Kadamberi, Hua Chang, Feng Wang, Sudhir Kumar, Shirng-Wern Tsaih, Christopher J. Walker, Pradeep Chaluvally-Raghavan, John Charlson, Yosef Landesman, Sunila Pradeep   +10 more
doaj   +1 more source

Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy [PDF]

, 2016
YesTumour suppressor proteins, such as p53, BRCA1, and ABC, play key roles in preventing the development of a malignant phenotype, but those that function as transcriptional regulators need to enter the nucleus in order to function.
Bethany Raynor, El-Habib Dakir, Matchett, Mohamed El-Tanani, Richard Morgan, Talarico, Vincent   +6 more
core   +2 more sources

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma [PDF]

, 2021
Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy.
Anderson L. D., Arazy M., Auner H. W., Badros A. Z., Bahlis N. J., Benjamin R., Cavo M., Chai Y., Delimpasi S., Dimopoulos M. A., Dolai T. K., Doronin V., Facon T., Garg M., Gavriatopoulou M., Grosicki S., Hajek R., Jagannath S., Jeha J., Kauffman M. G., Kriachok I., Leleu X., Levy M., Mateos M. V., Moreau P., Pour L., Pylypenko H., Quach H., Richardson P. G., Shacham S., Shah J., Simonova M., Sinha D. K., Spicka I., Stevens D. A., Usenko G., Venner C. P.   +36 more
core   +1 more source